100.39
price down icon0.44%   -0.44
pre-market  Pre-mercato:  99.77   -0.62   -0.62%
loading
Precedente Chiudi:
$100.83
Aprire:
$101.38
Volume 24 ore:
699.72K
Relative Volume:
1.10
Capitalizzazione di mercato:
$4.94B
Reddito:
$338.46M
Utile/perdita netta:
$-310.96M
Rapporto P/E:
-15.37
EPS:
-6.53
Flusso di cassa netto:
$-132.82M
1 W Prestazione:
-8.47%
1M Prestazione:
-2.87%
6M Prestazione:
-2.02%
1 anno Prestazione:
+16.02%
Intervallo 1D:
Value
$99.38
$102.15
Intervallo di 1 settimana:
Value
$99.38
$110.19
Portata 52W:
Value
$72.21
$139.13

Axsome Therapeutics Inc Stock (AXSM) Company Profile

Name
Nome
Axsome Therapeutics Inc
Name
Telefono
(212) 332-3241
Name
Indirizzo
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Name
Dipendente
589
Name
Cinguettio
Name
Prossima data di guadagno
2025-02-18
Name
Ultimi documenti SEC
Name
AXSM's Discussions on Twitter

Confronta AXSM con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
AXSM
Axsome Therapeutics Inc
100.39 4.96B 338.46M -310.96M -132.82M -6.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
460.83 120.60B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.63 60.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.79 42.87B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
595.19 36.23B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.51 31.54B 3.81B -644.79M -669.77M -6.24

Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-03 Ripresa Morgan Stanley Overweight
2025-06-03 Iniziato Oppenheimer Outperform
2025-04-07 Iniziato Jefferies Buy
2025-02-11 Iniziato Deutsche Bank Buy
2024-12-31 Reiterato Mizuho Outperform
2024-09-03 Iniziato Wells Fargo Overweight
2024-08-06 Aggiornamento BofA Securities Neutral → Buy
2024-07-22 Iniziato Needham Buy
2024-04-29 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2024-03-19 Iniziato Robert W. Baird Outperform
2024-02-06 Iniziato UBS Buy
2024-01-25 Iniziato RBC Capital Mkts Outperform
2023-12-13 Iniziato Citigroup Buy
2023-08-08 Aggiornamento BofA Securities Underperform → Neutral
2023-01-05 Iniziato Piper Sandler Neutral
2022-11-01 Iniziato Loop Capital Buy
2022-09-07 Ripresa Mizuho Buy
2021-08-10 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-06-10 Iniziato Berenberg Buy
2021-01-08 Iniziato Jefferies Buy
2020-12-16 Iniziato Mizuho Buy
2020-09-29 Iniziato BofA Securities Underperform
2020-09-10 Iniziato Morgan Stanley Overweight
2020-04-28 Reiterato H.C. Wainwright Buy
2020-04-14 Iniziato Cowen Outperform
2019-12-30 Reiterato H.C. Wainwright Buy
2019-12-17 Reiterato H.C. Wainwright Buy
2019-12-16 Reiterato Guggenheim Buy
2019-10-16 Iniziato Guggenheim Buy
2019-09-18 Iniziato William Blair Outperform
2019-05-28 Iniziato SunTrust Buy
2019-05-23 Reiterato H.C. Wainwright Buy
2019-04-08 Iniziato SVB Leerink Outperform
2019-03-15 Reiterato H.C. Wainwright Buy
2016-10-03 Ripresa Brean Capital Buy
2015-12-15 Iniziato Cantor Fitzgerald Buy
2015-12-14 Iniziato Ladenburg Thalmann Buy
Mostra tutto

Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie

pulisher
Jul 28, 2025

Axsome Therapeutics Inc.’s Price Action Aligns with Quant SignalsTriple Digit Return Stock Predictions Released - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance

Jul 28, 2025
pulisher
Jul 28, 2025

What makes Axsome Therapeutics Inc. stock price move sharplyStock Strategy Planner To Watch Now - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Envestnet Asset Management Inc. Sells 10,086 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jul 28, 2025
pulisher
Jul 28, 2025

Axsome Therapeutics (AXSM) to Release Earnings on Monday - MarketBeat

Jul 28, 2025
pulisher
Jul 28, 2025

Why is Axsome Therapeutics Inc. stock attracting strong analyst attentionAchieve rapid portfolio growth with expert guidance - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Royce & Associates LP Sells 6,743 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jul 28, 2025
pulisher
Jul 28, 2025

What catalysts could drive Axsome Therapeutics Inc. stock higher in 2025Invest confidently with real-time data analysis - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Does Axsome Therapeutics Inc. stock perform well during market downturnsGet timely alerts on market opportunities - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Universal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jul 28, 2025
pulisher
Jul 28, 2025

Cwm LLC Trims Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jul 28, 2025
pulisher
Jul 28, 2025

Y Intercept Hong Kong Ltd Makes New $1.49 Million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jul 28, 2025
pulisher
Jul 27, 2025

How strong is Axsome Therapeutics Inc. company’s balance sheetFree Market Dynamics Reports - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Axsome Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayFree Stock Market Query - metal.it

Jul 27, 2025
pulisher
Jul 27, 2025

Published on: 2025-07-27 23:41:07 - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Is Axsome Therapeutics Inc. stock overvalued or undervaluedDynamic profit expansion - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

When is Axsome Therapeutics Inc. stock expected to show significant growth - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How does Axsome Therapeutics Inc. generate profit in a changing economyUnprecedented profit potential - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Knights of Columbus Asset Advisors LLC Sells 4,957 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jul 27, 2025
pulisher
Jul 26, 2025

Q3 EPS Estimate for Axsome Therapeutics Raised by Analyst - MarketBeat

Jul 26, 2025
pulisher
Jul 25, 2025

Axsome Therapeutics: Navigating Setbacks with a Strong Pipeline and Analyst Confidence - AInvest

Jul 25, 2025
pulisher
Jul 25, 2025

Axsome: Some Recent Setbacks, Some Recent Wins — Still A Buy (NASDAQ:AXSM) - Seeking Alpha

Jul 25, 2025
pulisher
Jul 25, 2025

Axsome Therapeutics (NASDAQ:AXSM) Shares Down 5.6%Here's Why - MarketBeat

Jul 25, 2025
pulisher
Jul 25, 2025

Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline - ADVFN Brasil

Jul 25, 2025
pulisher
Jul 25, 2025

Why Axsome Therapeutics Inc. stock is on top investor watchlistsSuperior stock selection - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Axsome Therapeutics Inc. stockOutstanding capital growth - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

Axsome Therapeutics Inc. Stock Analysis and ForecastRapid growth trajectories - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stake Raised by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. - MarketBeat

Jul 25, 2025
pulisher
Jul 24, 2025

RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM) - The Globe and Mail

Jul 24, 2025
pulisher
Jul 24, 2025

New York State Common Retirement Fund Has $3.92 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jul 24, 2025
pulisher
Jul 24, 2025

Is Axsome Therapeutics Inc. stock overhyped or has real potentialUnstoppable trading performance - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

How high can Axsome Therapeutics Inc. stock price go in 2025Breakthrough investment results - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

How To Trade (AXSM) - news.stocktradersdaily.com

Jul 24, 2025
pulisher
Jul 24, 2025

Axsome Therapeutics Settles SUNOSI (Solriamfetol) Patent Litigation With Hetero Labs Ltd. - 富途牛牛

Jul 24, 2025
pulisher
Jul 24, 2025

Is This Stock a Buy After Soaring by 20% in 1 Day? - AOL.com

Jul 24, 2025
pulisher
Jul 24, 2025

2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now - MSN

Jul 24, 2025
pulisher
Jul 24, 2025

Legato Capital Management LLC Buys New Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jul 24, 2025
pulisher
Jul 24, 2025

Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today - 富途牛牛

Jul 24, 2025
pulisher
Jul 24, 2025

Is Axsome Therapeutics Inc. a good long term investmentGame-changing returns - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

Leerink Partners Keeps Bullish Stance on Axsome Therapeutics with Buy Rating - AInvest

Jul 23, 2025
pulisher
Jul 23, 2025

Lindbrook Capital LLC Cuts Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jul 23, 2025
pulisher
Jul 23, 2025

Optimistic Outlook for Axsome Therapeutics: Promising Pipeline and Potential Sales Growth Drive Buy Rating - TipRanks

Jul 23, 2025
pulisher
Jul 22, 2025

Axsome Therapeutics Breaks Below 200-Day Moving AverageNotable for AXSM - Nasdaq

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Axsome Therapeutics Inc. stock priceUnprecedented profit potential - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Readystate Asset Management LP Invests $6.95 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jul 22, 2025
pulisher
Jul 22, 2025

ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - The Globe and Mail

Jul 22, 2025
pulisher
Jul 22, 2025

Axsome Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada

Jul 22, 2025

Axsome Therapeutics Inc Azioni (AXSM) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Axsome Therapeutics Inc Azioni (AXSM) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Murdock Hunter R.
General Counsel
Jun 23 '25
Option Exercise
29.91
6,014
179,879
6,014
Murdock Hunter R.
General Counsel
Jun 20 '25
Sale
102.47
7,500
768,525
0
Murdock Hunter R.
General Counsel
Jun 23 '25
Sale
100.12
6,014
602,122
0
$23.09
price down icon 1.32%
$37.06
price up icon 1.06%
$101.75
price down icon 2.12%
$27.45
price down icon 4.26%
$112.79
price down icon 2.19%
biotechnology ONC
$294.51
price up icon 1.04%
Capitalizzazione:     |  Volume (24 ore):